SM

Suparna Mazumder

Cleveland Clinic Lerner College of Medicine-Case Western Reserve University, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, University of Calcutta

ORCID iD 0000-0002-9738-0040
Follow

About

I am an Emeritus Assistant Professor in the Department of Molecular Medicine at the CCLCM-CWRU and a scientific consultant at Anixa Biosciences, San Jose, California, Department of Biomedical Engineering, Cleveland Clinic, and Department of Small Animal Clinical Sciences, University of Florida. Throughout my research career, I have applied my substantial skills in cellular and molecular biology to the fields of breast and ovarian tumor immunology, mechanisms of drug resistance, and immunotherapy. These endeavors have yielded an extensive publication record, featuring numerous first, second, and corresponding authorship positions in high-impact journals. My current research focus is on the immunoprevention and immunotherapy of ovarian cancers.
We determined that the expression of the extracellular binding domain of the anti-Müllerian hormone receptor type 2 (AMHR2-ED) for the cognate ligand anti-Müllerian hormone (AMH) is a potentially targetable antigen for epithelial ovarian carcinoma (EOC) therapy, as it is confined exclusively to the ovary of normal adult women. Importantly, while the expression of AMH and AMHR2-ED disappears to undetectable levels in postmenopausal ovaries, AMHR2-ED is vastly overexpressed in EOCs. We have found that vaccination against the AMHR2-ED significantly inhibits the growth of murine EOC without causing clinically relevant systemic autoimmunity in young mice. We believe that safe and effective immunotherapy against EOC can be achieved by vaccinations targeting AMHR2-ED in women bearing EOC. Building on our finding that EOC inhibition was primarily mediated by AMHR2-ED-specific antibodies, we generated a mouse monoclonal antibody (mAb) targeting human AMHR2-ED and demonstrated its effectiveness against established EOCs. Furthermore, we generated the humanized variant of mouse AMHR2-ED mAb for clinical use. If successful, our current proposal offers two novel translational applications to control human EOCs. We have published articles in peer-reviewed journals based on novel approaches.
Previously, I did research studies on signaling pathways involved in drug resistance and selective approaches to overcome it in hematopoietic malignancies. I have studied the mechanism of cell cycle regulation, apoptosis, and oncogenesis using the human cellular model of both transformed and primary myeloid cells isolated from patients. The results obtained from my studies served as the basis of several successful NIH RO1 grant funding.
Additionally, I contributed to the research studies on therapeutic vaccination with the human alpha-lactalbumin protein against Triple-negative breast cancer (TNBC). I have published one article with my maiden name (Ghosh).

1) Issued Patent: OVARIAN CANCER VACCINES; U.S. Patent Number: 11090284; Year: 2021
2) Patent File: AMHR2-ED BINDING MOLECULES FOR TREATING DISEASES; Year: 2025

Employment

  • Cleveland Clinic Lerner College of Medicine-Case Western Reserve University Emeritus, Assistant Professor
    2024 - Present
  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine Assistant Professor
    2014 - 2023
  • Cleveland Clinic Project Staff
    2012 - 2023
  • Cleveland Clinic Project Staff
    2007 - 2012
  • Cleveland Clinic Research Associate
    2002 - 2007
  • Cleveland Clinic Postdoctoral Fellow
    1997 - 2002
  • Cleveland Clinic Postdoctoral Fellow
    1996 - 1997

Education

  • University of Calcutta Ph.D.
    ? - 1996
  • University of Calcutta M.S.
    ? - 1986
  • University of Calcutta B.S,
    ? - 1984

Projects & Funding

Projects & funding information is unavailable.

Publications (28)